Endocannabinoid Metabolism and Transport as Drug Targets.
2-Arachidonoylglycerol
Anandamide
Drug design
Metabolic routes
Signal transduction
Transport mechanisms
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
24
9
2022
pubmed:
25
9
2022
medline:
28
9
2022
Statut:
ppublish
Résumé
The wide distribution of the endocannabinoid system (ECS) throughout the body and its pivotal pathophysiological role offer promising opportunities for the development of novel therapeutic drugs for treating several diseases. However, the need for strategies to circumvent the unwanted psychotropic and immunosuppressive effects associated with cannabinoid receptor agonism/antagonism has led to considerable research in the field of molecular alternatives, other than type-1 and type-2 (CB
Identifiants
pubmed: 36152188
doi: 10.1007/978-1-0716-2728-0_16
doi:
Substances chimiques
Endocannabinoids
0
Receptors, Cannabinoid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
201-211Informations de copyright
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Pacher P, Bátkai S, Kunos G (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58:389. https://doi.org/10.1124/PR.58.3.2
doi: 10.1124/PR.58.3.2
pubmed: 16968947
Hu W-R, Lian Y-F, Peng L-X, Lei J-J, Deng C-C, Xu M, Feng Q-S, Chen L-Z, Bei J-X, Zeng Y-X (2014) Monoacylglycerol lipase promotes metastases in nasopharyngeal carcinoma. Int J Clin Exp Pathol 7:3704–3713
pubmed: 25120746
pmcid: 4128981
Gong X, Zheng X, Huang Y, Song W, Chen G, Chen T (2022) Monoacylglycerol lipase (MAGL) inhibition impedes the osteosarcoma progression by regulating epithelial mesenchymal transition. Tohoku J Exp Med 256:19–26. https://doi.org/10.1620/TJEM.256.19
doi: 10.1620/TJEM.256.19
pubmed: 35067491
Kokona D, Spyridakos D, Tzatzarakis M, Papadogkonaki S, Filidou E, Arvanitidis KI, Kolios G, Lamani M, Makriyannis A, Malamas MS et al (2021) The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity. Neuropharmacology 185:108450. https://doi.org/10.1016/J.NEUROPHARM.2021.108450
doi: 10.1016/J.NEUROPHARM.2021.108450
pubmed: 33450278
Deng H, van der Stelt M (2018) Chemical tools to modulate 2-arachidonoylglycerol biosynthesis. Biotechnol Appl Biochem 65:9–15. https://doi.org/10.1002/bab.1568
doi: 10.1002/bab.1568
pubmed: 28589628
Aronne LJ, Tonstad S, Moreno M, Gantz I, Erondu N, Suryawanshi S, Molony C, Sieberts S, Nayee J, Meehan AG et al (2010) A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond) 34:919–935. https://doi.org/10.1038/IJO.2010.21
doi: 10.1038/IJO.2010.21
Samat A, Tomlinson B, Taheri S, Thomas GN (2008) Rimonabant for the treatment of obesity. Recent Pat Cardiovasc Drug Discov 3:187–193. https://doi.org/10.2174/157489008786264014
doi: 10.2174/157489008786264014
pubmed: 18991793
Bisogno T, Mahadevan A, Coccurello R, Chang JW, Allarà M, Chen Y, Giacovazzo G, Lichtman A, Cravatt B, Moles A et al (2012) Themed Section Cannabinoids. https://doi.org/10.1111/bph.2013.169.issue-4
Shin M, Snyder HW, Donvito G, Schurman LD, Fox TE, Lichtman AH, Kester M, Hsu KL (2018) Liposomal delivery of diacylglycerol lipase-beta inhibitors to macrophages dramatically enhances selectivity and efficacy in vivo. Mol Pharm 15:721–728. https://doi.org/10.1021/acs.molpharmaceut.7b00657
doi: 10.1021/acs.molpharmaceut.7b00657
pubmed: 28901776
Gregus AM, Buczynski MW Druggable targets in endocannabinoid signaling. https://doi.org/10.1007/978-3-030-50621-6_8
Mock ED, Mustafa M, Gunduz-Cinar O, Cinar R, Petrie GN, Kantae V, Di X, Ogasawara D, Varga ZV, Paloczi J et al (2020) Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice. Nat Chem Biol 16:667–675. https://doi.org/10.1038/s41589-020-0528-7
doi: 10.1038/s41589-020-0528-7
pubmed: 32393901
pmcid: 7468568
Trang T (2007) Inhibition of fatty acid amide hydrolase: a potential treatment for neuropathic pain. J Neurosci 27:3364–3365. https://doi.org/10.1523/JNEUROSCI.0583-07.2007
doi: 10.1523/JNEUROSCI.0583-07.2007
pubmed: 17392451
pmcid: 6672129
Woodhams SG, Wong A, Barrett DA, Bennett AJ, Chapman V, Alexander SPH (2012) Spinal administration of the monoacylglycerol lipase inhibitor JZL184 produces robust inhibitory effects on nociceptive processing and the development of central sensitization in the rat. Br J Pharmacol 167:1609–1619. https://doi.org/10.1111/J.1476-5381.2012.02179.X
doi: 10.1111/J.1476-5381.2012.02179.X
pubmed: 22924700
pmcid: 3525864
Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A et al (2002) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76–81. https://doi.org/10.1038/nm803
doi: 10.1038/nm803
pubmed: 12461523
Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL et al (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A 106:20270–20275. https://doi.org/10.1073/PNAS.0909411106/SUPPL_FILE/SM3.MOV
doi: 10.1073/PNAS.0909411106/SUPPL_FILE/SM3.MOV
pubmed: 19918051
pmcid: 2787168
Busquets-Garcia A, Puighermanal E, Pastor A, De La Torre R, Maldonado R, Ozaita A (2011) Differential role of anandamide and 2-arachidonoylglycerol in memory and anxiety-like responses. Biol Psychiatry 70:479–486. https://doi.org/10.1016/J.BIOPSYCH.2011.04.022
doi: 10.1016/J.BIOPSYCH.2011.04.022
pubmed: 21684528
Bedse G, Bluett RJ, Patrick TA, Romness NK, Gaulden AD, Kingsley PJ, Plath N, Marnett LJ, Patel S (2018) Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors. Transl Psychiatry 8:92. https://doi.org/10.1038/s41398-018-0141-7
doi: 10.1038/s41398-018-0141-7
pubmed: 29695817
pmcid: 5917016
Rubino T, Zamberletti E, Parolaro D (2015) Endocannabinoids and Mental Disorders. Handb Exp Pharmacol 231:261–283. https://doi.org/10.1007/978-3-319-20825-1_9
doi: 10.1007/978-3-319-20825-1_9
pubmed: 26408164
Zhang Z, Wang W, Zhong P, Liu SJ, Long JZ, Zhao L, Gao H-Q, Cravatt BF, Liu Q-S Blockade of 2-arachidonoylglycerol hydrolysis produces antidepressant-like effects and enhances adult hippocampal neurogenesis and synaptic plasticity. Hippocampus. https://doi.org/10.1002/hipo.22344
Kaur R, Sidhu P, Singh S (2016) What failed BIA 10-2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials
Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, Di Marzo V (2009) Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34:593–606. https://doi.org/10.1038/npp.2008.98
doi: 10.1038/npp.2008.98
pubmed: 18580871
Viveros-Paredes JM, Gonzalez-Castañeda RE, Escalante-Castañeda A, Tejeda-Martínez AR, Castañeda-Achutiguí F, Flores-Soto ME (2019) Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage. Neurologia (Engl Ed) 34:143
doi: 10.1016/j.nrl.2016.11.008
Greco R, Demartini C, Zanaboni A, Casini I, De Icco R, Reggiani A, Misto A, Piomelli D, Tassorelli C (2021) Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine. Neurobiol Dis 147:105157. https://doi.org/10.1016/J.NBD.2020.105157
doi: 10.1016/J.NBD.2020.105157
pubmed: 33129939
Griebel G, Stemmelin J, Lopez-Grancha M, Fauchey V, Slowinski F, Pichat P, Dargazanli G, Abouabdellah A, Cohen C, Bergis OE (2018) The selective reversible FAAH inhibitor, SSR411298, restores the development of maladaptive behaviors to acute and chronic stress in rodents. Sci Rep 8:2416. https://doi.org/10.1038/S41598-018-20895-Z
doi: 10.1038/S41598-018-20895-Z
pubmed: 29403000
pmcid: 5799259
Pawsey S, Wood M, Browne H, Donaldson K, Christie M, Warrington S (2016) Safety, tolerability and pharmacokinetics of FAAH inhibitor V158866: a double-blind, randomised, placebo-controlled phase I study in healthy volunteers. Drugs R D 16:181. https://doi.org/10.1007/s40268-016-0127-y
doi: 10.1007/s40268-016-0127-y
pubmed: 26987975
pmcid: 4875922
Li GL, Winter H, Arends R, Jay GW, Le V, Young T, Huggins JP (2012) Assessment of the pharmacology and tolerability of PF-04457845, an irreversible inhibitor of fatty acid amide hydrolase-1, in healthy subjects. Br J Clin Pharmacol 73:706–716. https://doi.org/10.1111/j.1365-2125.2011.04137.x
doi: 10.1111/j.1365-2125.2011.04137.x
pubmed: 22044402
Mulvihill MM, Nomura DK (2014) Therapeutic potential of MAGL inhibitors. Life Sci 92:492–497. https://doi.org/10.1016/j.lfs.2012.10.025.Therapeutic
doi: 10.1016/j.lfs.2012.10.025.Therapeutic
Kerr DM, Harhen B, Okine BN, Egan LJ, Finn DP, Roche M, Roche M (2012) The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action. Br J Pharmacol 169:808. https://doi.org/10.1111/bph.2013.169.issue-4
doi: 10.1111/bph.2013.169.issue-4
Marino S, de Ridder D, Bishop RT, Renema N, Ponzetti M, Sophocleous A, Capulli M, Aljeffery A, Carrasco G, Gens MD et al (2019) Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice. EBioMedicine 44:452–466. https://doi.org/10.1016/J.EBIOM.2019.05.048
doi: 10.1016/J.EBIOM.2019.05.048
pubmed: 31151929
pmcid: 6606522
Deng H, Li W (2020) Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders. Acta Pharm Sin B 10:582–602. https://doi.org/10.1016/J.APSB.2019.10.006
doi: 10.1016/J.APSB.2019.10.006
pubmed: 32322464
Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D, Booker L, Burston JJ et al (2010) Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 13:1113–1119. https://doi.org/10.1038/NN.2616
doi: 10.1038/NN.2616
pubmed: 20729846
pmcid: 2928870
Kirsten Müller-Vahl AR, Fremer C, Beals C, Ivkovic J, Loft H, Schindler C, Thieme Verlag GK, Müller-Vahl KR, Müller-Vahl KR et al (2022) Monoacylglycerol lipase inhibition in tourette syndrome … pharmacopsychiatry | endocannabinoid modulation using monoacylglycerol lipase inhibition in tourette syndrome: a phase 1 randomized, placebo-controlled study. Pharmacopsychiatry 55:148. https://doi.org/10.1055/a-1675-3494
doi: 10.1055/a-1675-3494
pubmed: 34847610
Bononi G, Poli G, Rizzolio F, Tuccinardi T, Macchia M, Minutolo F, Granchi C (2021) An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present). Expert Opin Ther Pat 31:153–168. https://doi.org/10.1080/13543776.2021.1841166
doi: 10.1080/13543776.2021.1841166
pubmed: 33085920
Oddi S, Fezza F, Pasquariello N, D’Agostino A, Catanzaro G, De Simone C, Rapino C, Finazzi-Agrò A, Maccarrone M (2009) Molecular identification of albumin and Hsp70 as cytosolic anandamide-binding proteins. Chem Biol 16:624–632. https://doi.org/10.1016/j.chembiol.2009.05.004
doi: 10.1016/j.chembiol.2009.05.004
pubmed: 19481477
Hillard CJ, Jarrahian A (2000) The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids 108:123–134. https://doi.org/10.1016/S0009-3084(00)00191-2
doi: 10.1016/S0009-3084(00)00191-2
pubmed: 11106786
Maccarrone M, Dainese E, Oddi S (2010) Intracellular trafficking of anandamide: new concepts for signaling. Trends Biochem Sci 35:601–608. https://doi.org/10.1016/j.tibs.2010.05.008
doi: 10.1016/j.tibs.2010.05.008
pubmed: 20570522
Albakova Z, Armeev GA, Kanevskiy LM, Kovalenko EI, Sapozhnikov AM (2020) HSP70 multi-functionality in cancer. Cells 9:587
doi: 10.3390/cells9030587
Leboffe L, Di Masi A, Trezza V, Polticelli F, Ascenzi P (2017) Hypothesis human serum albumin: a modulator of cannabinoid drugs. IUBMB Life 69:834–840. https://doi.org/10.1002/iub.1682
doi: 10.1002/iub.1682
pubmed: 28976704
Masato F, Hotamisligil Gökhan S (2008) Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7:489. https://doi.org/10.1038/nrd2589
doi: 10.1038/nrd2589
Kaczocha M, Rebecchi MJ, Ralph BP, Teng YHG, Berger WT, Galbavy W, Elmes MW, Glaser ST, Wang L, Rizzo RC et al (2014) Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. PLoS One 9:e94200. https://doi.org/10.1371/JOURNAL.PONE.0094200
doi: 10.1371/JOURNAL.PONE.0094200
pubmed: 24705380
pmcid: 3976407
Lijffijt M, Janiri L, Thanos PK, Clavin BH, Hamilton J, O’rourke JR, Maher T, Koumas C, Miao E, Lankop J et al (2016) Examination of the addictive and behavioral properties of fatty acid-binding protein inhibitor sBFi26. Front Psychiatry 7:54. https://doi.org/10.3389/fpsyt.2016.00054
doi: 10.3389/fpsyt.2016.00054
Battista N, Gasperi V, Fezza F, Maccarrone M (2005) The anandamide membrane transporter and the therapeutic implications of its inhibition. Therapy 2:141–150. https://doi.org/10.1586/14750708.2.1.141
doi: 10.1586/14750708.2.1.141
Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D (1997) Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277:1094–1097. https://doi.org/10.1126/SCIENCE.277.5329.1094
doi: 10.1126/SCIENCE.277.5329.1094
pubmed: 9262477
Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V (2003) Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 65:1473–1481. https://doi.org/10.1016/S0006-2952(03)00109-6
doi: 10.1016/S0006-2952(03)00109-6
pubmed: 12732359
López-Rodríguez ML, Viso A, Ortega-Gutiérrez S, Lastres-Becker I, González S, Fernández-Ruiz J, Ramos JA (2001) Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J Med Chem 44:4505–4508. https://doi.org/10.1021/jm015545y
doi: 10.1021/jm015545y
pubmed: 11741470
Alexander JP, Cravatt BF (2006) The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases. J Am Chem Soc 128:9699–9704. https://doi.org/10.1021/JA062999H
doi: 10.1021/JA062999H
pubmed: 16866524
Fegley D, Kathuria S, Mercier R, Li C, Goutopoulos A, Makriyannis A, Piomelli D (2004) Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A 101:8756–8761. https://doi.org/10.1073/PNAS.0400997101/ASSET/0CB214B2-5868-4FF0-A16A-AA02004FD430/ASSETS/GRAPHIC/ZPQ0210449340005.JPEG
doi: 10.1073/PNAS.0400997101/ASSET/0CB214B2-5868-4FF0-A16A-AA02004FD430/ASSETS/GRAPHIC/ZPQ0210449340005.JPEG
pubmed: 15138300
pmcid: 423268
Chicca A, Nicolussi S, Bartholomäus R, Blunder M, Rey AA, Petrucci V, Reynoso-Moreno IDC, Viveros-Paredes JM, Gens MD, Lutz B et al (2017) Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake. Proc Natl Acad Sci U S A 114:E5006–E5015. https://doi.org/10.1073/PNAS.1704065114/-/DCSUPPLEMENTAL
doi: 10.1073/PNAS.1704065114/-/DCSUPPLEMENTAL
pubmed: 28584105
pmcid: 5488949
Reynoso-Moreno I, Tietz S, Vallini E, Engelhardt B, Gertsch J, Chicca A (2021) Selective endocannabinoid reuptake inhibitor WOBE437 reduces disease progression in a mouse model of multiple sclerosis. ACS Pharmacol Transl Sci 4:765–779. https://doi.org/10.1021/ACSPTSCI.0C00214
doi: 10.1021/ACSPTSCI.0C00214
pubmed: 33860200
pmcid: 8033750
Reynoso-Moreno I, Chicca A, Flores-Soto ME, Viveros-Paredes JM, Gertsch J (2018) The endocannabinoid reuptake inhibitor WOBE437 is orally bioavailable and exerts indirect polypharmacological effects via different endocannabinoid receptors. Front Mol Neurosci 11:180. https://doi.org/10.3389/FNMOL.2018.00180/BIBTEX
doi: 10.3389/FNMOL.2018.00180/BIBTEX
pubmed: 29910713
pmcid: 5992379